Clinical Trials
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
Imetelstat as Maintenance Therapy After Chemotherapy in Lung Cancer
Helpful Information
- Maintenance therapy is treatment given to help keep cancer from coming back after it has disappeared following the initial therapy.
- Induction therapy is the initial treatment used to reduce a cancer. It is also called first-line therapy, primary therapy, and primary treatment.
- Platinum is a metal that is an important component of some anti-cancer drugs such as cisplatin and carboplatin.
- Progression-free survival (PFS) is the length of time during and after treatment in which the cancer does not get worse.
- Objective response rate measures how many patients in the study have had either a partial or complete response to treatment.
- Standard of care is a treatment that experts agree is appropriate, accepted, and widely used. It is also often called best practice, standard medical care, or standard therapy.
A Randomized Phase 2 Study of Imetelstat (GRN163L) as Maintenance Therapy After Initial Induction Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Geron is enrolling patients in a clinical trial to evaluate the potential benefit of our product candidate, imetelstat, as maintenance therapy for patients with advanced stage NSCLC. This study is open to patients who have not progressed, meaning their cancer has not worsened, after platinum-based induction chemotherapy.
In this Phase 2 clinical trial, our clinical researchers and investigators will be evaluating how maintenance therapy with imetelstat impacts the progression-free survival rates of patients with NSCLC.
Additionally, we are collecting data on the objective response rate in patients.
Upon acceptance to the study, patients will be assigned by chance or “randomized” to separate groups that compare results of treatment with imetelstat in addition to standard of care against standard of care alone. Patients who were randomized to the control arm will be given the option to receive imetelstat at the end of the study.
In this study the standard of care is observation or observation with bevacizumab. Patients who previously received bevacizumab with their induction chemotherapy will continue to receive bevacizumab in this study.
Imetelstat is an investigational treatment for cancer in development by Geron and has not been approved by the FDA or any other regulatory agency.
About Imetelstat
Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely. One of Geron's potential anti-cancer strategies is to stop or slow down the growth and spread of tumors by inhibiting telomerase activity. Learn more
Cancer Definitions
To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.
Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de cáncer en un recurso útil.
How to Participate
To learn more about if you are eligible to participate in this clinical trial, please visit ClinicalTrials.gov for the full trial summary and enrollment criteria.
Additionally, patients or their physicians may directly contact the nearest trial center for more information about how to participate. The study is currently being conducted in multiple centers across the United States and Germany.
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
